Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

AbbVie (NYSE:ABBV) announced Monday a setback for a Phase 3 trial designed to test its Roche (OTCQX:RHHBF)-partnered leukemia ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Roche entered into a Licensing, Development, and Commercialisation agreement with Prothena in December 2013 to develop and ...

Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson’s disease.

Roche/Genentech entered into a Licensing, Development, and Commercialization agreement with Prothena in December 2013 to develop and commercialize monoclonal antibodies targeting aggregated ...